Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.
Akwabi-Ameyaw, A., Bass, J.Y., Caldwell, R.D., Caravella, J.A., Chen, L., Creech, K.L., Deaton, D.N., Jones, S.A., Kaldor, I., Liu, Y., Madauss, K.P., Marr, H.B., McFadyen, R.B., Miller, A.B., III, F.N., Parks, D.J., Spearing, P.K., Todd, D., Williams, S.P., Wisely, G.B.(2008) Bioorg Med Chem Lett 18: 4339-4343
- PubMed: 18621523 
- DOI: https://doi.org/10.1016/j.bmcl.2008.06.073
- Primary Citation of Related Structures:  
3DCT, 3DCU - PubMed Abstract: 
Starting from the known FXR agonist GW 4064 1a, a series of stilbene replacements were prepared. The 6-substituted 1-naphthoic acid 1b was an equipotent FXR agonist with improved developability parameters relative to 1a. Analog 1b also reduced the severity of cholestasis in the ANIT acute cholestatic rat model.
- Department of Medicinal Chemistry, GlaxoSmithKline, 5 Moore Drive, PO Box 13398, Research Triangle Park, NC 27709, USA.
Organizational Affiliation: